NIH Stroke Scale (NIHSS) is a standardized, 15-item neurological examination instrument designed to provide a quantitative, objective measure of acute stroke-related impairment. Originally developed in 1989 as a research tool for the National Institute of Neurological Disorders and Stroke (NINDS) t-PA stroke trials, it has since become the global clinical benchmark for evaluating acute stroke severity, predicting clinical outcomes, and guiding emergent reperfusion therapies1,2. The scale evaluates crucial domains of neurological function, including level of consciousness, visual fields, extraocular movements, facial symmetry, motor strength in all four limbs, limb ataxia, sensory modalities, language (aphasia), dysarthria, and neglect or inattention. Because acute stroke management relies on rapid, reproducible assessment, the NIHSS allows clinicians across emergency departments, pre-hospital settings, and specialized stroke units to communicate neurological status with high inter-rater reliability, monitor dynamic clinical deterioration, and select appropriate candidates for intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT)2,3,4.

1. Etiology & Risk Factors

  • Cerebrovascular Pathologies: Acute ischemic stroke caused by cardioembolic sources (e.g., atrial fibrillation), large-artery atherosclerosis, small-vessel lacunar occlusion, or cryptogenic etiologies leading to sudden focal neurological deficits quantified by the NIHSS5,6.
  • Hemorrhagic Mechanisms: Primary intracerebral hemorrhage (ICH) resulting from chronic hypertension, cerebral amyloid angiopathy, or anticoagulant therapy (e.g., vitamin K antagonists or direct oral anticoagulants), yielding high baseline NIHSS scores due to mass effect and tissue disruption6.
  • Vascular Risk Factors: Advanced age, arterial hypertension, diabetes mellitus, dyslipidemia, smoking, excessive alcohol consumption, and prior transient ischemic attack (TIA) or stroke.
  • Systemic Triggers: Prothrombotic states, systemic hypoperfusion, severe dehydration, and cardiac arrhythmias precipitating acute focal ischemia with acute elevation in neurological scoring.

2. Pathophysiology

The pathophysiological foundation of the NIHSS relies on mapping focal cerebral ischemia or hemorrhage to specific anatomical brain regions and their corresponding neurological functions. When a cerebral artery—such as the middle cerebral artery (MCA)—is acutely occluded, cerebral blood flow drops below the ischemic threshold (less than 10-12 mL/100g/min), triggering rapid cellular energy failure, cytotoxic edema, and loss of neuronal membrane polarization. Depending on the affected vascular territory, this structural disruption manifests as distinct clinical deficits captured by the scale items: ischemia of the motor cortex or internal capsule produces contralateral hemiparesis (items 5 and 6); involvement of Broca's or Wernicke's areas results in aphasia (item 9); damage to the frontal eye fields or brainstem pathways causes gaze deviation (item 2); and parietal lobe ischemia leads to hemispatial neglect or sensory extinction (item 11). The cumulative score directly reflects the volume of dysfunctional yet potentially salvageable ischemic penumbra surrounding the necrotic core, guiding urgent therapeutic reperfusion strategies1,3,7.

NIH Stroke Scale (NIHSS) — Pathophysiological Cascade & Clinical Flowchart 1 Acute Focal Ischemia Acute cerebral arterial occlusion leading to localized hypoperfusion and immediate cytotoxic energy failure 2 Neurological Deficit Generation Rapid dysfunction of cerebral networks manifesting as measurable motor, sensory, visual, and language deficits 3 Standardized Quantification Systematic evaluation using the 15-item NIHSS to assign objective severity points reflecting functional tissue compromise 4 Clinical Score Stratification Categorization of stroke severity into minor (0-5), moderate (6-15), severe (16-20), and very severe (>20) categories 5 Therapeutic Decision Making Guided administration of reperfusion therapies and post-stroke monitoring to optimize functional recovery and reduce disability

3. Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Sudden onset of focal neurological deficits, including acute unilateral weakness or numbness, facial drooping, slurred speech or complete inability to speak, visual field cuts, sudden severe vertigo with ataxia, and acute confusion or loss of consciousness.
  • Physical Examination & Named Clinical Signs:
    • Contralateral Hemiparesis / Hemiplegia: Weakness affecting the face, arm, and leg on one side of the body, evaluated via drift and antigravity tests (NIHSS items 4, 5, and 6).
    • Expressive and Receptive Aphasia: Impairment in speech production, naming, and comprehension of spoken or written language (NIHSS item 9).
    • Dysarthria: Slurred, poorly articulated speech resulting from impaired motor control of the speech musculature (NIHSS item 10).
    • Extinction and Inattention (Neglect): Failure to attend to visual, tactile, or auditory stimuli on the side opposite the cerebral lesion (NIHSS item 11).
    • Conjugate Gaze Deviation: Forced deviation of the eyes away from the paretic side, often indicating an acute hemispheric stroke (NIHSS item 2).

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationStandardized 15-item clinical NIHSS scoring combined with emergent non-contrast head CT to exclude intracranial hemorrhage and evaluate early ischemic signs.
Laboratory PanelPoint-of-care blood glucose (to exclude hypoglycemia mimicking stroke), complete blood count, platelet count, serum electrolytes, renal function panel, and coagulation profile (PT/INR, aPTT) prior to thrombolysis.
Imaging / Radiology (X-ray, US, CT, MRI)Non-contrast CT showing absence of hemorrhage and potential early ischemic signs (e.g., hyperdense MCA sign, loss of insular ribbon, sulcal effacement); CT angiography (CTA) demonstrating large vessel occlusion; perfusion CT or MRI demonstrating core infarct versus salvageable penumbra.
ECG / Histopathology / Procedural12-lead ECG and telemetry to identify acute myocardial infarction, atrial fibrillation, or conduction abnormalities; transesophageal or transthoracic echocardiography to investigate cardioembolic sources in cryptogenic strokes or embolic strokes of undetermined source (ESUS)5.

5. Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Level of Consciousness (Items 1a, 1b, 1c)Evaluates alertness, orientation to month and age, and command execution (0-3 points per sub-item; higher scores indicate severe encephalopathy or coma).
Best Gaze & Visual Fields (Items 2 & 3)Assesses horizontal eye movements (0-2 points) and visual field confrontation/extinction (0-3 points); detects brainstem or hemispheric pathway disruption.
Facial Palsy & Motor Limbs (Items 4, 5, 6)Grades facial asymmetry (0-3 points) and drift/movement in bilateral upper and lower extremities (0-4 points per limb); guides motor deficit quantification and large vessel occlusion probability.
Limb Ataxia & Sensory (Items 7 & 8)Tests appendicular ataxia via finger-nose-finger and heel-knee-shin tests (0-2 points) and pinprick sensation across dermatomes (0-2 points).
Language, Dysarthria & Extinction (Items 9, 10, 11)Evaluates aphasia severity (0-3 points), speech articulation clarity (0-2 points), and neglect/inattention (0-2 points); crucial for localizing cortical hemisphere involvement.
Overall NIHSS Severity StratificationScore 0: No stroke symptoms; Score 1-5: Minor stroke; Score 6-15: Moderate stroke; Score 16-20: Moderate-to-severe stroke; Score 21-42: Severe stroke. Guides triage for IVT and EVT interventions1,2,6.

6. Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
HypoglycemiaPresents with acute focal neurological deficits or altered mental status mimicking stroke; immediately reversed upon intravenous dextrose administration with normal neuroimaging.
Todd's ParesisTransient post-ictal focal motor deficit following a generalized or focal seizure; rapid clinical resolution over hours and absence of acute ischemia on neuroimaging.
Complicated Migraine / Hemiplegic MigraineEpisodic headache preceded by transient visual, sensory, or motor symptoms spreading gradually; normal structural neuroimaging and history of similar recurrent episodes.
Intracranial Mass / NeoplasmProgressive focal neurological deficits rather than hyperacute onset; neuroimaging reveals space-occupying lesion with surrounding vasogenic edema and mass effect.

7. Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Secure airway, breathing, and circulation (ABCs); maintain oxygen saturation above 94%; monitor cardiac rhythm; strictly manage blood pressure (target systolic BP < 185 mmHg and diastolic BP < 110 mmHg prior to thrombolysis); and correct hypoglycemia immediately.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing):
    • Intravenous Thrombolysis (IVT): Alteplase administered at 0.9 mg/kg (maximum dose 90 mg) intravenously over 60 minutes, with 10% of the total dose given as an initial bolus over 1 minute, administered within 4.5 hours of symptom onset for eligible acute ischemic stroke patients2,3. Alternatively, tenecteplase administered as a single IV bolus of 0.25 mg/kg (maximum 25 mg).
    • Antiplatelet Therapy: Aspirin 162 mg to 325 mg administered orally within 24 to 48 hours after stroke onset for patients not receiving thrombolysis.
  • Surgical / Interventional Indications: Urgent endovascular mechanical thrombectomy (EVT) for patients with acute ischemic stroke presenting within 24 hours of last known well with a confirmed large vessel occlusion in the anterior circulation (and selected posterior circulation cases) and a baseline NIHSS score $\ge 6$. Decompressive craniectomy is indicated for malignant middle cerebral artery infarctions exhibiting severe cerebral edema and mass effect.

8. Complications & Prognosis

  • Acute Complications: Symptomatic intracranial hemorrhage (sICH) following thrombolysis or thrombectomy, malignant cerebral edema with uncal herniation, hemorrhagic transformation of ischemic infarct, aspiration pneumonia, deep vein thrombosis, and pulmonary embolism3,6.
  • Prognostic Factors: Baseline NIHSS score is the single strongest independent predictor of functional outcome and mortality; higher baseline scores (>20) correlate with large infarct volumes, high risk of hemorrhagic transformation, and poor 90-day functional independence (modified Rankin Scale score 0-2). Age, baseline blood pressure, admission hyperglycemia, and successful recanalization via thrombectomy significantly modify long-term prognosis2,3.